Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by W. A. Messersmith
Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) With Erlotinib (OSI-774): Early Termination Due to Increased Toxicities
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Adjuvant Chemoradiation for Gastric Cancer With Infusional 5-Fluorouracil and Cisplatin: A Phase I Study
Current Oncology
Oncology
5 Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as a Third-Line Chemotherapy Treatment in Metastatic Gastric Cancer, After Failure of Fluoropyrimidine, Platinum, Anthracycline, and Taxane
Bosnian Journal of Basic Medical Sciences
Medicine
Celecoxib and Mucosal Protection: Translation From an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil
Clinical Cancer Research
Cancer Research
Oncology
Liposomal Irinotecan and 5-Fluorouracil/Leucovorin in Older Patients With Metastatic Pancreatic Cancer – A Subgroup Analysis of the Pivotal NAPOLI-1 Trial
Journal of Geriatric Oncology
Gerontology
Geriatrics
Oncology
Quality of Life in Metastatic Pancreatic Cancer Patients Receiving Liposomal Irinotecan Plus 5-Fluorouracil and Leucovorin
European Journal of Cancer
Cancer Research
Oncology
Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients With Advanced Non-Small Cell Lung Cancer and a Performance Status of 2
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
A Phase I Pharmacologic and Pharmacogenetic Trial of Sequential 24-Hour Infusion of Irinotecan Followed by Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients With Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Serum Iron Levels as a New Biomarker in Chemotherapy With Leucovorin and Fluorouracil Plus Oxaliplatin or Leucovorin and Fluorouracil Plus Irinotecan, With or Without Molecularly-Targeted Drugs
Molecular and Clinical Oncology
Cancer Research
Oncology
